KR20150130419A - 세포외 기질 결합성 합성 펩티도글리칸 - Google Patents

세포외 기질 결합성 합성 펩티도글리칸 Download PDF

Info

Publication number
KR20150130419A
KR20150130419A KR1020157028095A KR20157028095A KR20150130419A KR 20150130419 A KR20150130419 A KR 20150130419A KR 1020157028095 A KR1020157028095 A KR 1020157028095A KR 20157028095 A KR20157028095 A KR 20157028095A KR 20150130419 A KR20150130419 A KR 20150130419A
Authority
KR
South Korea
Prior art keywords
synthetic peptidoglycan
collagen
binding peptide
binding
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157028095A
Other languages
English (en)
Korean (ko)
Inventor
알리사 파니치
존 에릭 파데리
샤일리 샤르마
캐서린 앨리슨 스튜어트
넬라 마리 바즈퀘즈-포탈라틴
Original Assignee
시믹 바이오메디칼, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시믹 바이오메디칼, 인크. filed Critical 시믹 바이오메디칼, 인크.
Publication of KR20150130419A publication Critical patent/KR20150130419A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Marine Sciences & Fisheries (AREA)
KR1020157028095A 2013-03-15 2014-03-14 세포외 기질 결합성 합성 펩티도글리칸 Withdrawn KR20150130419A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798916P 2013-03-15 2013-03-15
US61/798,916 2013-03-15
PCT/US2014/029596 WO2014144969A1 (en) 2013-03-15 2014-03-14 Extracellular matrix-binding synthetic peptidoglycans

Publications (1)

Publication Number Publication Date
KR20150130419A true KR20150130419A (ko) 2015-11-23

Family

ID=51537842

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028095A Withdrawn KR20150130419A (ko) 2013-03-15 2014-03-14 세포외 기질 결합성 합성 펩티도글리칸

Country Status (14)

Country Link
US (3) US9200039B2 (enExample)
EP (1) EP2970509B1 (enExample)
JP (1) JP6603650B2 (enExample)
KR (1) KR20150130419A (enExample)
AU (1) AU2014233537A1 (enExample)
BR (1) BR112015022917A2 (enExample)
CA (1) CA2903450A1 (enExample)
EA (1) EA201591454A1 (enExample)
HK (1) HK1220217A1 (enExample)
IL (1) IL241054A0 (enExample)
MX (1) MX2015012608A (enExample)
SG (1) SG11201506966RA (enExample)
WO (1) WO2014144969A1 (enExample)
ZA (1) ZA201506391B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2720368T3 (es) 2008-03-27 2019-07-19 Purdue Research Foundation Peptidoglicanos sintéticos de enlace a colágeno, preparación y método de utilización
PL2714718T3 (pl) 2011-05-24 2017-11-30 Symic Ip, Llc Syntetyczne peptydoglikany wiążące kwas hialuronowy, otrzymywanie i sposoby zastosowania
WO2014144969A1 (en) 2013-03-15 2014-09-18 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CA2956137A1 (en) 2014-05-12 2015-11-19 Alyssa Panitch Selectin and icam/vcam peptide ligand conjugates
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
JP6693728B2 (ja) * 2014-11-14 2020-05-13 興和株式会社 新規な機能性ペプチド
US10463769B2 (en) 2014-12-19 2019-11-05 Northwestern University Thromboresistant-anticoagulant extracellular matrix
WO2016161333A2 (en) * 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
BR112017021970A2 (pt) * 2015-04-17 2018-07-10 Symic Ip Llc bioconjugados e usos dos mesmos
US10463745B2 (en) * 2015-05-12 2019-11-05 Northwestern University Materials for tissue regeneration
EP3512561A4 (en) 2016-09-16 2020-10-07 Glycologix, LLC SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMETICS
WO2019010485A1 (en) * 2017-07-07 2019-01-10 Symic Ip, Llc TREATMENT OF FIBROSIS
KR20240148963A (ko) 2017-07-07 2024-10-11 시믹 아이피, 엘엘씨 합성 생체접합체
AU2018298226B2 (en) * 2017-07-07 2024-06-06 Symic Ip, Llc Biconjugates with chemically modified backbones
US12036234B2 (en) 2017-10-11 2024-07-16 Northwestern University Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues
US20240245791A1 (en) * 2021-06-02 2024-07-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors
EP4580751A2 (en) 2022-09-29 2025-07-09 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
JPWO2024080183A1 (enExample) * 2022-10-14 2024-04-18

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683298A (en) 1985-01-10 1987-07-28 British Columbia Research Council Process for the preparation of aminated polysaccharide derivatives
US5547936A (en) 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
CA2006060A1 (en) 1988-12-20 1990-06-20 Michael D. Pierschbacher Polypeptide-polymer conjugates active in wound healing
FR2644066B1 (fr) 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
US5693625A (en) 1989-03-09 1997-12-02 Therapeutiques Substitutives Method of regenerating cells and tissues using functionalized dextrans
WO1992012175A1 (en) 1991-01-14 1992-07-23 New York University Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof
JP2901787B2 (ja) 1991-07-15 1999-06-07 日本メジフィジックス株式会社 核磁気共鳴造影剤
FR2718023B1 (fr) 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
EP1704878B1 (en) 1995-12-18 2013-04-10 AngioDevice International GmbH Crosslinked polymer compositions and methods for their use
CA2299687C (en) 1997-08-04 2009-10-27 Bio Syntech Ltd. Temperature-controlled ph-dependant formation of ionic polysaccharide gels
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
BR9814878A (pt) 1997-11-21 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
US7691829B2 (en) 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
JP3103531B2 (ja) 1998-09-30 2000-10-30 延也 柳内 ヒト尿由来細胞接着糖蛋白質及びその製造方法
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20110214206A1 (en) 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
FR2794976B1 (fr) 1999-06-16 2004-05-07 Solutions Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
DE60043736D1 (de) 1999-09-15 2010-03-11 Euclid Systems Corp Zusammensetzung zur stabilisierung des corneagewebon kontaktlinsen
FR2799465B1 (fr) 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
US20030158302A1 (en) 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
DE60003459T2 (de) 1999-12-09 2004-05-06 Biosyntech Canada Inc., Laval Mineral-polymer hybrid-zusammensetzung
US7671018B2 (en) 2000-08-30 2010-03-02 University Of Delaware Delivery system for heparin-binding growth factors
US7803905B2 (en) 2000-08-31 2010-09-28 University Of Delaware Bioactive peptide for cell adhesion
AU2002211517A1 (en) 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
DE60125973D1 (de) 2000-11-15 2007-02-22 Biosyntech Canada Inc Verfahren zur wiederherstellung einer geschädigten bandscheibe
US20040236092A1 (en) 2001-07-13 2004-11-25 Roman Dziarski Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof
CA2455884C (en) 2001-08-15 2015-09-22 Justin R. Fallon Treatment of muscular dystrophies and related disorders
WO2003042250A1 (en) 2001-11-15 2003-05-22 Biosyntech Canada Inc. Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US20090158452A1 (en) 2001-12-04 2009-06-18 Johnson Richard G Transgenic plants with enhanced agronomic traits
CA2478675A1 (en) 2002-03-08 2003-09-18 Zymogenetics, Inc. Inhibitors for use in hemostasis
US7666852B2 (en) 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
JP2005185101A (ja) 2002-05-30 2005-07-14 National Institute Of Agrobiological Sciences 植物の全長ｃＤＮＡおよびその利用
US7862831B2 (en) 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US8673333B2 (en) 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
US20090183270A1 (en) 2002-10-02 2009-07-16 Adams Thomas R Transgenic plants with enhanced agronomic traits
EP1570045A4 (en) 2002-10-04 2007-09-05 Univ Minnesota NUCLEIC ACID AND POLYPEPTIDE SEQUENCES FROM LAWSONIA INTRACELLULARIS AND METHOD OF USE
US20050069572A1 (en) 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
FR2846659B1 (fr) 2002-10-30 2005-02-18 Centre Nat Rech Scient Fragments peptidiques du facteur harp inhibant l'angiogenese
US20040127416A1 (en) 2002-11-15 2004-07-01 Massia Stephen P. Therapeutic bioconjugates
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
FR2861308A1 (fr) 2003-10-28 2005-04-29 Organes Tissus Regeneration Re Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs
DE602004029068D1 (de) 2003-10-28 2010-10-21 Organes Verwendung von biokompatiblen polymeren zur herstekts
EP1694247A2 (en) 2003-12-15 2006-08-30 Technion Research And Development Foundation, Ltd. Therapeutic drug-eluting endoluminal covering
EP1722834B1 (en) 2003-12-22 2012-06-27 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US7709439B2 (en) 2004-02-20 2010-05-04 Boston Scientific Scimed, Inc. Biomaterials for enhanced healing
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
EP1758931A1 (en) 2004-05-31 2007-03-07 National University of Singapore Peptides derived from decorin leucine rich repeats and uses thereof
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
WO2006036681A2 (en) 2004-09-22 2006-04-06 Cartilix, Inc. Cartilage filling device
US20090202616A1 (en) 2004-09-29 2009-08-13 National University Of Singapore Composite, Method of Producing the Composite and Uses of the Same
US20060241022A1 (en) 2004-10-06 2006-10-26 Bowen Benjamin P Selectin targeting bioconjugates
WO2006047758A1 (en) 2004-10-27 2006-05-04 Massachusetts Institute Of Technology Novel technique to fabricate molded structures having a patterned porosity
US8283414B2 (en) 2004-11-23 2012-10-09 The Johns Hopkins University Compositions comprising modified collagen and uses therefor
WO2006089167A1 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Glucosamine materials
WO2006089119A2 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
EP1853917A4 (en) 2005-03-04 2008-09-10 Univ Northwestern ANGIOGENIC HEPARIN BINDING EPITOPES, PEPTIDE AMPHIPHILES, SELF-ASSEMBLED COMPOSITIONS AND METHODS OF USE THEREOF
GB2424223C (en) 2005-03-07 2011-02-02 Massachusetts Inst Technology Biomaterial.
US8431226B2 (en) 2005-03-30 2013-04-30 Biomet Manufacturing Corp. Coated medical device
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8338390B2 (en) 2005-03-31 2012-12-25 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8367639B2 (en) 2005-03-31 2013-02-05 University Of Delaware Hydrogels with covalent and noncovalent crosslinks
US7737131B2 (en) 2005-03-31 2010-06-15 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8415325B2 (en) 2005-03-31 2013-04-09 University Of Delaware Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels
EP2478760A1 (en) 2005-05-10 2012-07-25 Monsanto Technology LLC Genes and uses for plant improvement
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
US20080069774A1 (en) 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
JP2009529374A (ja) 2006-03-07 2009-08-20 アクスル インターナショナル 治療及び癒着防止用生物活性スキャホールド
US20070212385A1 (en) 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
CA2645324A1 (en) 2006-03-15 2007-09-27 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
EP2090662A3 (en) 2006-04-05 2012-10-31 Metanomics GmbH Process for the production of a fine chemical
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20090162436A1 (en) 2006-06-14 2009-06-25 Carson Daniel D Compositions and methods for repair of tissues
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US8114834B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles
US8114835B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles for tissue engineering
US20100222546A1 (en) 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
US8188220B2 (en) 2006-12-06 2012-05-29 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting wounds, regenerating tissue, and tumors
US20080295196A1 (en) 2006-12-06 2008-11-27 Abad Mark S Genes and uses for plant improvement
PT2150282T (pt) 2007-04-16 2018-07-09 Regentis Biomaterials Ltd Composições e métodos para formação do suporte
KR20100005105A (ko) 2007-05-06 2010-01-13 민병현 세포외 기질 지지체를 이용한 연골질환 치료용 조성물
WO2008152639A2 (en) 2007-06-12 2008-12-18 Bypass, Inc. Pressure pulse actuating device for delivery systems
US20090075281A1 (en) 2007-07-10 2009-03-19 Regents Of The University Of California Mtbe genes
US7993679B2 (en) 2007-09-25 2011-08-09 Integra Lifesciences Corporation Flowable wound matrix and its preparation and use
US20100210509A1 (en) 2007-10-09 2010-08-19 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
WO2009099580A2 (en) 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
ES2720368T3 (es) 2008-03-27 2019-07-19 Purdue Research Foundation Peptidoglicanos sintéticos de enlace a colágeno, preparación y método de utilización
CA2719666C (en) 2008-04-04 2016-08-16 Glenn Prestwich Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
US20100004196A1 (en) 2008-06-17 2010-01-07 Hopitaux Universitaires De Geneve Heparan sulfate proteoglycan composition and use thereof
WO2010011857A2 (en) 2008-07-23 2010-01-28 The Johns Hopkins University Parenteral administration of a glucosamine
US20110269208A1 (en) 2008-08-15 2011-11-03 The Trustees Of The University Of Pennsylvania Cross-linked polymer network formed by sequential cross-linking
CN102216460A (zh) 2008-09-17 2011-10-12 希尔雷斯股份有限公司 生物量增加的转基因植物
FR2936247B1 (fr) 2008-09-24 2010-10-22 Ct Hospitalier Universitaire De Dijon Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire.
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8859706B2 (en) 2008-11-28 2014-10-14 Zetascience Gmbh Bioactive hydrogel
KR101062068B1 (ko) 2008-12-01 2011-09-02 포항공과대학교 산학협력단 유착방지용 조성물
IL195764A0 (en) 2008-12-07 2009-11-18 Technion Res & Dev Foundation Compositions and methods for drug delivery
US9012723B2 (en) 2009-01-16 2015-04-21 Monsanto Technology Llc Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
BRPI1013179A2 (pt) 2009-03-30 2019-09-24 Prometheus Laboratories Inc peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado
US20110182862A1 (en) 2009-04-03 2011-07-28 Green Wayne A Endophytic fungus and uses therefor
EP2419116A1 (en) 2009-04-13 2012-02-22 North Western University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
FI20095452A0 (fi) 2009-04-23 2009-04-23 Suomen Punainen Risti Veripalv Uudet haaraiset sokerianalyysit
WO2010129547A1 (en) 2009-05-04 2010-11-11 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
EP2499167A4 (en) 2009-11-09 2013-07-10 Univ Drexel COMPOSITIONS AND METHODS FOR TREATING AN ILLNESS OR MALFUNCTION IN SOFT TISSUE
AU2010325908A1 (en) 2009-12-04 2012-06-07 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
DK2513294T3 (en) 2009-12-16 2016-06-06 Regentis Biomaterials Ltd SKELETS FOR POLYMER-PROTEIN CONJUGATES, PROCEDURES FOR GENERATION THEREOF AND APPLICATIONS THEREOF
WO2011094149A1 (en) 2010-01-26 2011-08-04 University Of Utah Research Foundation Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
EP2538957B1 (en) 2010-02-26 2019-07-24 Vascular Biosciences, Inc. Car peptide for homing, diagnosis,&targeted therapy for pulmonary and fibrotic disorders
ES2742218T3 (es) 2010-06-23 2020-02-13 Purdue Research Foundation Peptidoglicanos sintéticos que se enlazan al colágeno destinados a ser utilizados en operaciones vasculares
US9173919B2 (en) 2011-02-16 2015-11-03 Purdue Research Foundation Collagen-targeted nanoparticles
WO2012149515A2 (en) 2011-04-29 2012-11-01 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
PL2714718T3 (pl) 2011-05-24 2017-11-30 Symic Ip, Llc Syntetyczne peptydoglikany wiążące kwas hialuronowy, otrzymywanie i sposoby zastosowania
EP2804586A4 (en) 2012-01-19 2016-03-16 Univ Johns Hopkins BIOMATERIALS CONTAINING HYALURONIC ACID BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMERMOLUCKS FOR HYALURONIC ACIDIC TREATMENT AND TISSUE RENEWAL APPLICATIONS
US9540428B2 (en) 2012-07-03 2017-01-10 Ecole Polytechnique Federale De Lausanne (Epfl) Extracellular matrix heparin-binding domains
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
WO2014038866A1 (ko) 2012-09-05 2014-03-13 아주대학교산학협력단 연골세포 유래 세포외 기질막을 이용한 신생혈관질환 치료용 조성물 및 각막 또는 결막 이식재
DE102012108560B4 (de) 2012-09-13 2018-12-20 Leibniz-Institut Für Polymerforschung Dresden E.V. Nichtkovalente selbstorganisierende Hydrogelmatrix für biotechnologische Anwendungen
CN104870020A (zh) 2012-10-19 2015-08-26 康奈尔大学 用于关节软骨的仿生型界面润滑剂
US20150291672A1 (en) 2012-11-01 2015-10-15 The Johns Hopkins University Contact Lens Surface Modification with Hyaluronic Acid (HA) Binding Peptide for HA Accumulation and Retention
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
WO2014144969A1 (en) 2013-03-15 2014-09-18 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
US9543849B2 (en) 2013-04-16 2017-01-10 Panasonic Intellectual Property Management Co., Ltd. Power conversion apparatus, power conversion method, motor system, and three-phase motor
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CA2956137A1 (en) 2014-05-12 2015-11-19 Alyssa Panitch Selectin and icam/vcam peptide ligand conjugates
WO2016061145A1 (en) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
WO2016061147A1 (en) 2014-10-13 2016-04-21 John Eric Paderi Luminal vessel coating for arteriovenous fistula
WO2016065083A1 (en) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
WO2016161333A2 (en) 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
BR112017021970A2 (pt) 2015-04-17 2018-07-10 Symic Ip Llc bioconjugados e usos dos mesmos
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate

Also Published As

Publication number Publication date
US20160129076A1 (en) 2016-05-12
EP2970509A1 (en) 2016-01-20
HK1220217A1 (zh) 2017-04-28
US9872887B2 (en) 2018-01-23
US20140288002A1 (en) 2014-09-25
EP2970509B1 (en) 2020-05-13
JP2016516065A (ja) 2016-06-02
EA201591454A1 (ru) 2015-12-30
MX2015012608A (es) 2016-07-06
JP6603650B2 (ja) 2019-11-06
US20190022175A1 (en) 2019-01-24
US9200039B2 (en) 2015-12-01
EP2970509A4 (en) 2016-11-02
ZA201506391B (en) 2017-09-27
WO2014144969A1 (en) 2014-09-18
CA2903450A1 (en) 2014-09-18
IL241054A0 (en) 2015-11-30
SG11201506966RA (en) 2015-10-29
AU2014233537A1 (en) 2015-09-10
BR112015022917A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
JP6603650B2 (ja) 細胞外マトリックス結合性合成ペプチドグリカン
US20220313830A1 (en) Heparin-peptide bioconjugates and uses thereof
JP6502311B2 (ja) ヒアルロン酸結合合成ペプチドグリカン、その製造および使用方法
US20170112941A1 (en) Ve-cadherin binding bioconjugate
KR20170016857A (ko) 셀렉틴 및 icam/vcam 펩티드 리간드 접합체
WO2016161333A2 (en) Compositions comprising bioconjugates
WO2008081463A2 (en) Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
ES3021835T3 (en) Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
EP3294312B1 (en) Materials for tissue regeneration
JP2015527307A (ja) 胎盤成長因子からの配列を含有するコンジュゲートならびに生体材料および医薬の成分としてのその使用
WO2016065083A1 (en) Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
US20210100832A1 (en) Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
WO2025049740A1 (en) Compositions comprising biomimetic proteoglycan constructs
CN120187439A (zh) 细胞植体与类胶原蛋白的多功能肽组合物及其应用
WO2020205602A1 (en) Glycocalyx mimetic coatings
HK1231093A1 (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
HK1196839B (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
HK1196839A (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151008

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20170418

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid